Roche Moving Two Novel Biotech Agents Into Phase III In 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Continuous-acting erythropoietin CERA and rheumatoid arthritis agent MRA will join ovarian cancer treatment pemtumomab to give Roche a total of three novel Phase III agents in 2004. All three biotech agents are projected for filing in next five years.
You may also be interested in...
New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting
Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.
New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting
Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.
Roche Has “Reasonable” Chance Of Launching Its Long-Acting EPO In U.S.
Roche believes is has a "reasonable" chance of being able to launch its long-acting EPO product CERA in the U.S. upon approval despite expected patent challenges, the company said Sept. 13 at the Bear Stearns health care conference in New York.